Study Backs Controversial Blood-Thinning Drug (Reuters)


Reuters - A blood-thinning drug not approved for
the U.S. market because of questions about liver damage appears
to be as effective as other common therapies for preventing
strokes and recurring blood clots, according to studies
published on Tuesday.

Read more...